Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Zeposia | ozanimod | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Zeposia | ozanimod | Multiple Sclerosis, relapsing - remitting | Do not reimburse | Complete | ||
Ozanex | ozenoxacin | Impetigo | Do not reimburse | Complete | ||
Ibrance | Palbociclib | Withdrawn | ||||
Ibrance Resubmission | Palbociclib | Advanced breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Ibrance (with Faslodex) | Palbociclib (with Fulvestrant) | Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Invega | Paliperidone | Schizophrenia | Do not list | Complete | ||
Invega Sustenna | Paliperidone palmitate | Schizophrenia | Do not list | Complete | ||
Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | |||
Aloxi (injection) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list at the submitted price | Complete |